BioEnclave Products Now Available at Faridpur Diabetic Association Hospital

Faridpur Diabetic Association Hospital has expanded its advanced wound care capabilities through the inclusion of BioEnclave's CuraGel and AmnioVive, strengthening the availability of innovative wound management solutions for the local healthcare community.

As a leading healthcare institution serving a large patient population, Faridpur Diabetic Association Hospital plays an important role in the management of chronic and complex wounds. The inclusion of CuraGel and AmnioVive within the hospital ecosystem reflects a shared commitment to supporting modern wound care practices and improving access to advanced healthcare technologies.

BioEnclave continues to work closely with healthcare providers, hospitals, and medical professionals across Bangladesh to ensure that innovative solutions are available where they are needed most. Through strong institutional partnerships and ongoing professional engagement, the company aims to contribute to the continued advancement of wound care management throughout the country.

Both CuraGel and AmnioVive were developed with a focus on quality, innovation, and patient-centered care. Their availability at Faridpur Diabetic Association Hospital marks another important milestone in BioEnclave's mission to deliver advanced healthcare solutions to clinicians and patients nationwide.

Quality remains a cornerstone of BioEnclave's operations. The company operates under an ISO 9001-certified Quality Management System, reinforcing its commitment to maintaining high standards across its organizational processes and continuous improvement initiatives.